Three decades of transplantation for chronic myeloid leukemia: what have we learned?

Single-Unit Umbilical Cord Blood Transplantation from Unrelated Donors in Adult Patients with Chronic Myelogenous Leukemia

(2010) Jaime Sanz et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Optimizing patient selection for myeloablative allogeneic hematopoietic cell transplantation in chronic myeloid leukemia in chronic phase

(2010) J. Pavlu et al.   BLOOD

Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome

(2010) Marcos de Lima et al.   CANCER

Relapse and Late Mortality in 5-Year Survivors of Myeloablative Allogeneic Hematopoietic Cell Transplantation for Chronic Myeloid Leukemia in First Chronic Phase

(2010) John M. Goldman et al.   JOURNAL OF CLINICAL ONCOLOGY

Standardisation of molecular monitoring for chronic myeloid leukaemia

(2009) Nicholas C.P. Cross   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

The blast phase of chronic myeloid leukaemia

(2009) Richard T. Silver   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV

(2009) S. Saussele et al.   BLOOD

The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up

(2009) R. J. Garg et al.   BLOOD

Outcome of patients developing GVHD after DLI given to treat CML relapse: a study by the chronic leukemia working party of the EBMT

(2009) Y Chalandon et al.   BONE MARROW TRANSPLANTATION

Risk score for outcome after allogeneic hematopoietic stem cell transplantation

(2009) Alois Gratwohl et al.   CANCER

Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia

(2009) D. Milojkovic et al.   HAEMATOLOGICA

Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet

(2009) Michele Baccarani et al.   JOURNAL OF CLINICAL ONCOLOGY

Sustained major molecular response in the absence of any antileukaemic therapy after dasatinib treatment and autologous peripheral blood stem cell transplantation in a patient with imatinib-resistant myeloblastic-phase chronic myeloid leukaemia

(2009) D Rea et al.   LEUKEMIA

Can we include vaccines with stem-cell transplantation?

(2009) John Barrett et al.   Nature Reviews Clinical Oncology

Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia

(2008) S. J. Lee et al.   BLOOD

Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia

(2008) C. S. Tam et al.   BLOOD

European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor

(2008) D. Marin et al.   BLOOD

Unrelated cord blood transplantation in CML: Japan Cord Blood Bank Network analysis

(2008) T Nagamura-Inoue et al.   BONE MARROW TRANSPLANTATION

Imatinib for Newly Diagnosed Patients With Chronic Myeloid Leukemia: Incidence of Sustained Responses in an Intention-to-Treat Analysis

(2008) Hugues de Lavallade et al.   JOURNAL OF CLINICAL ONCOLOGY

Hematopoietic stem cells and progenitors of chronic myeloid leukemia express leukemia-associated antigens: implications for the graft-versus-leukemia effect and peptide vaccine-based immunotherapy

(2008) A S M Yong et al.   LEUKEMIA